Últimas noticias sobre Gain Therapeutics (NASDAQ:GANX) Bolsa

Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

AZTR

GANX

SILO

Descubre las últimas transacciones de insiders en penny stocks como ALZN, GANX, AZTR y SILO. ¡Aprovecha esta información privilegiada ahora!

Compras de insiders de penny stocks: ALZN, GANX, AZTR, SILO

Gain Therapeutics Inc

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has reportedly found some units of <a href="https://www.benzinga.com/topic/cybertruck">Cybertruck</a> with "cell dent" issues and the company has started replacing battery packs of those cars.
What Happened: According to a report <a href="https://electrek.co/2024/12/20/tesla-finds-cell-dent-issues-in-cybertrucks-starts-replacing-battery-packs/">by</a> Electrek, citing sources familiar with the matter, Tesla has identified the cell dent issue with some Cybertruck units and it has begun sending them back to Gigafactory Texas to solve the problem.
Tesla identified the issue in several inventory vehicles but has not found it in customer-delivered models. The Cybertruck is unique among Tesla&#8217;s lineup as the only vehicle using the company's in-house 4680 battery cells.
Tesla currently produces several thousand Cybertrucks weekly at Gigafactory Texas but has already issued multiple recalls. Many owners have reported frequent service visits, with some even asking Tesla if it would buy back those faulty units.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No, I don't really want to talk about it &#x1f34b; After several failures in our sub 1500 VIN Cybertruck including but not limited to: front motor inverter, rear motor inverter, rear wheel steering, and more under 25k mi, I asked if Tesla would consider buying it back. Overall it's been… <a href="https://t.co/g0n7gvJeho">pic.twitter.com/g0n7gvJeho</a>
&mdash; The Kilowatts &#x1f697;&#x26a1;&#xFE0F; (@klwtts) <a href="https://twitter.com/klwtts/status/1869814610049806737?ref_src=twsrc%5Etfw">December 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: While Tesla has big ambitions for the Cybertruck, it has recently faced demand hurdles. The EV giant reportedly <a href="https://www.benzinga.com/24/12/42501487/cybertruck-production-rate-was-reduced-even-before-decembers-production-pause-says-tesla-researcher">reduced the production rate</a> of the Cybertruck, with over 9,000 units still in its inventory.
According to Tesla researcher Troy Teslike, Cybertruck production was reduced by over 55% on Nov. 10.
Tesla also <a href="https://www.benzinga.com/24/12/42283708/tesla-gives-cybertruck-production-line-workers-three-days-off-report">announced a three-day production pause</a>, giving workers on the Cybertruck line paid time off.
Another sign of possible demand hurdles is that Tesla is <a href="https://www.benzinga.com/tech/24/12/42524912/teslas-99k-foundation-series-cybertrucks-still-available-a-sign-of-possible-demand-hurdles">still selling</a> its premium $99,990 foundation series Cybertruck, suggesting that it has not yet sold out all of its inventory.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42523474/alphabets-waymo-expands-global-reach-with-tokyo-robotaxi-testing-eyes-left-hand-traffic-challenges" target="_blank" rel="noreferrer noopener">Alphabet's Waymo Expands Global Reach With Tokyo Robotaxi Testing, Eyes Left-Hand Traffic Challenges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Cybertruck Units Reportedly Found With Cell Dent Issues: EV Giant Starts Replacing Battery Packs

On Friday, ChatGPT-maker OpenAI unveiled its next-generation reasoning model, o3, as the successor to o1, capping off the company's <a href="https://www.benzinga.com/tech/24/12/42332451/sam-altman-teases-12-days-of-openai-christmas-magic-users-predict-unveiling-of-sora-o1-reasoning-model-and-more">12 days of shipmas</a> announcements.
What Happened: On the final day of its &#8220;12 Days of OpenAI&#8221; event, the AI startup revealed o3, which brings significant advancements in reasoning and coding capabilities.
Alongside o3, Microsoft Corp.-backed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) OpenAI also introduced o3-mini, a smaller version designed for specific, more targeted applications.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We announced <a href="https://twitter.com/OpenAI?ref_src=twsrc%5Etfw">@OpenAI</a> o1 just 3 months ago. Today, we announced o3. We have every reason to believe this trajectory will continue. <a href="https://t.co/Ia0b63RXIk">pic.twitter.com/Ia0b63RXIk</a>
&mdash; Noam Brown (@polynoamial) <a href="https://twitter.com/polynoamial/status/1870172996650053653?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/12/42509206/soundhound-ai-soars-over-700-short-squeeze-potential-has-traders-talking?itm_source=parsely-api">SoundHound AI Soars 700%: Short Squeeze Potential Has Traders Talking</a>
"We view this as the beginning of the next phase of AI. Where you can use these models to do increasingly complex tasks that require a lot of reasoning," stated OpenAI CEO Sam Altman.
The company has begun rolling out o3 to select safety researchers, with plans for broader availability soon. The application window closes on Jan. 10.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">if you are a safety researcher, please consider applying to help test o3-mini and o3. excited to get these out for general availability soon. extremely proud of all of openai for the work and ingenuity that went into creating these models; they are great.
&mdash; Sam Altman (@sama) <a href="https://twitter.com/sama/status/1870176283851903152?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Altman also stated that the o3-mini may launch by the end of January, followed by the full release of the o3 model.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Notably, OpenAI skipped over naming the new model &#8220;o2,&#8221; to avoid potential trademark conflicts with British telecom provider O2, <a href="https://www.theinformation.com/briefings/openai-announces-new-reasoning-model-o3">according</a> to The Information.
Why It Matters: OpenAI's progress is evident in the ARC-AGI benchmark, where o3 scored 87.5% on the high compute setting, tripling o1's performance on the lower setting.
The ARC-AGI test is often used to measure progress toward achieving Artificial General Intelligence (AGI) by assessing a model's performance in areas that require advanced problem-solving and reasoning.
However, ARC-AGI co-creator François Chollet also noted that o3 struggles with "very easy tasks" in ARC-AGI, suggesting it has "fundamental differences" from human intelligence.&nbsp;
&#8220;While the new model is very impressive and represents a big milestone on the way towards AGI, I don&#8217;t believe this is AGI &#8212; there&#8217;s still a fair number of very easy ARC-AGI-1 tasks that o3 can&#8217;t solve, and we have early indications that ARC-AGI-2 will remain extremely challenging for o3,&#8221; Chollet stated.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Today OpenAI announced o3, its next-gen reasoning model. We&#39;ve worked with OpenAI to test it on ARC-AGI, and we believe it represents a significant breakthrough in getting AI to adapt to novel tasks. It scores 75.7% on the semi-private eval in low-compute mode (for $20 per task… <a href="https://t.co/ESQ9CNVCEA">pic.twitter.com/ESQ9CNVCEA</a>
&mdash; François Chollet (@fchollet) <a href="https://twitter.com/fchollet/status/1870169764762710376?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As part of its &#8220;12 Days of OpenAI&#8221; event, the AI startup rolled out the ChatGPT Search engine to all users, <a href="https://www.benzinga.com/tech/24/12/42523020/chatgpt-search-goes-free-openai-challenges-googles-unbroken-search-dominance">including those on the free tier</a>.
The AI startup also unveiled its text-to-image model, Sora, and introduced a $200 monthly ChatGPT Pro <a href="https://www.benzinga.com/tech/24/12/42356469/openai-unveils-200-chatgpt-pro-subscription-inside-the-o1-reasoning-model-and-what-it-means-for-power-users">subscription</a>.
Earlier this month, Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) also launched the <a href="https://www.benzinga.com/24/12/42446686/google-introduces-ai-agent-prototype-that-can-browse-the-web">second generation</a> of its Gemini AI model to regain its position at the forefront of the AI technology race.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42499609/micron-gets-investment-from-white-house-china-launches-antitrust-investigation-on-nvidia-apple-faces-1-2-billion-lawsuit-in-california-more-consumer-tech-news-december-9-13?itm_source=parsely-api">Micron Gets Investment From White House, China Launches Antitrust Investigation On Nvidia, Apple Faces $1.2 Billion Lawsuit In California &amp; More: Consumer Tech News</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

GOOG

GOOGL

MSFT

ChatGPT Maker OpenAI Drops o3 Reasoning Model As o1's Successor: Greg Brockman Calls It A 'Breakthrough'

Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) bagged a key win <a href="https://www.benzinga.com/news/global/24/12/42520522/arm-qualcomm-face-off-in-court-what-to-expect-from-silicon-soap-opera">in its legal battle</a> against semiconductor design company Arm Holdings Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>).
What Happened: A federal jury in Delaware ruled that Qualcomm did not violate its licensing agreement with Arm, clearing a hurdle for the San Diego, California headquartered chipmaker.
Qualcomm's win was the result of a mistrial after the jury could not resolve one of the three questions put before it for deliberation. This means Arm can take Qualcomm to the court once again in the future.
While the ruling said Qualcomm did not breach its licensing agreement with Arm, the jury could not determine if Nuvia is guilty of doing so. Nuvia is a startup that was acquired by Qualcomm in 2021 for $1.4 billion.
Qualcomm used Nuvia to bolster its Snapdragon X line of chips that power some Windows laptops. The company projected savings of up to $1.4 billion a year thanks to Nuvia acquisition.
See Also: <a href="https://www.benzinga.com/markets/equities/24/12/42378342/intel-stock-is-where-it-was-27-years-ago-how-the-worlds-leading-chipmaker-lost-the-plot-thrice">Intel Stock Is Where It Was 27 Years Ago: How The World&#8217;s Leading Chipmaker Lost The Plot, Thrice</a>
Why It Matters: SoftBank Group-backed Arm <a href="https://www.benzinga.com/markets/equities/24/10/41481425/softbank-backed-arm-threatens-to-cancel-qualcomms-chip-design-license-ahead-of-trial-in-december">threatened to cancel</a> Qualcomm's chip design license ahead of the December trial.
Qualcomm's chips power many Android smartphones and tablets – these chip sales account for a large portion of the company's $39 billion revenue.
The company called it an attempt to "strong-arm a longtime partner."
"We are confident that Qualcomm&#8217;s rights under its agreement with Arm will be affirmed," a Qualcomm spokesperson said, according to the report.
Price Action: Qualcomm stock gained over 1.8% in after-hours trading to hover around $152.89, while Arm stock fell by over 1.4% to $132.15, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42310095/apple-shares-hit-new-high-despite-iphone-sales-slowdown-expert-reiterates-that-street-is-starting-to-realize-iphone-16-is-the-start-of-a-super-cycle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AAPL Stock Hits New High Despite Sales Slowdown: Tech Bull Says ‘Street Is Realizing&#8217; iPhone 16 Marks The ‘Start Of A Super Cycle&#8217; For Apple</a></li>
</ul>
Photo courtesy: Qualcomm

Legal

QCOM

Qualcomm Bags Win In Chips Licensing Trial Against Arm, But The Battle Is Not Over Yet

Tesla and SpaceX CEO Elon Musk, who had earlier expressed skepticism over Speaker Mike Johnson's (R-La.) latest plan, shifted his stance after the passage of a spending package to avert a government shutdown.
What Happened: Taking to X, formerly Twitter, Musk praised Johnson's efforts saying, "The Speaker did a good job here, given the circumstances. It went from a bill that weighed pounds to a bill that weighed ounces."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Speaker did a good job here, given the circumstances. It went from a bill that weighed pounds to a bill that weighed ounces. Ball should now be in the Dem court. <a href="https://t.co/KnSwLEjvjd">https://t.co/KnSwLEjvjd</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1870236798267298044?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/09/41016869/mike-johnson-vows-no-christmas-omnibus-breaking-from-a-terrible-tradition-were-not-going-to-do-any-b">Mike Johnson Vows No Christmas Omnibus, Breaking From A &#8216;Terrible Tradition&#8217;: &#8216;We&#8217;re Not Going To Do Any Buses, OK?&#8217;</a>
Musk had previously questioned whether Johnson's plan, which involved a vote on the failed bill without a debt ceiling provision, was more aligned with Republicans or Democrats.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">So is this a Republican bill or a Democrat bill? &#x1f914; <a href="https://t.co/C54cbLGoGR">https://t.co/C54cbLGoGR</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1870210936616755632?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
On Friday, the House of Representatives <a href="https://www.benzinga.com/news/24/12/42633817/house-passes-spending-bill-to-avert-government-shutdown-sidesteps-trumps-demand-to-suspend-federal-debt-limi">passed a stopgap funding measure</a>, narrowly avoiding a government shutdown just hours before the deadline.
Following the passage of a spending package to avert a government shutdown, House minority leader Hakeem Jeffries (D-N.Y.) said, &#8220;House Democrats have successfully stopped extreme MAGA Republicans from shutting down the government, crashing the economy, and hurting working-class Americans all across the land.&#8221;
In response to Jeffries' comments, Musk sarcastically congratulated him on the spending bill victory. His post featured a stack of documents split into two piles—one significantly larger than the other—seemingly critiquing the complexity of legislative processes.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Congratulations on your "victory", <a href="https://twitter.com/RepJeffries?ref_src=twsrc%5Etfw">@RepJeffries</a> lol <a href="https://t.co/uxtHKXOamZ">pic.twitter.com/uxtHKXOamZ</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1870241934511329359?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The House&#8217;s decision came after a week of intense Republican infighting.
Speaker Johnson had initially brokered a bipartisan funding deal with Democrats, but it was derailed by <a href="https://www.benzinga.com/general/social-media/24/12/42566558/house-republicans-reject-spending-bill-under-pressure-from-trump-musk-government-faces-shutdown">opposition from both</a> President-elect Donald Trump and Musk.
&#8220;Your elected representatives have heard you and now the terrible bill is dead. The voice of the people has triumphed,&#8221; the tech mogul posted on X at the time.
To avoid a government shutdown set for midnight on Friday, Republican leaders unveiled a &#8220;Plan C.&#8221;&nbsp;
This strategy involved holding separate votes on three crucial measures: a short-term funding bill to extend government operations for three months, a $100 billion disaster relief package, and a $10 billion farm aid bill.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41762294/mike-johnson-urges-calm-on-result-certification-the-election-is-too-big-to-rig">Mike Johnson Urges Calm On Result Certification: The Election Is &#8216;Too Big To Rig&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Government

Politics

Elon Musk Changes Tone, Applauds Speaker Johnson: 'It Went From A Bill That Weighed Pounds To One That Weighed Ounces'

On Friday, the House of Representatives approved a stopgap funding bill, just hours before a <a href="https://www.benzinga.com/24/12/42544562/congressional-leaders-reach-bipartisan-deal-to-avert-government-shutdown">potential government shutdown</a>.
What Happened: The legislation, which extends funding into mid-March and includes disaster relief, now moves to the Senate, <a href="https://www.nytimes.com/live/2024/12/20/us/government-shutdown-trump-news">reported</a> the New York Times.
The bill passed with a vote of 366 to 34, with all &#8220;no&#8221; votes coming from Republicans, and one Democrat, Jasmine Crockett of Texas, voting present.
See Also: <a href="https://www.benzinga.com/24/12/42545204/marjorie-taylor-greene-pushes-to-sell-off-usps-amid-doge-momentum-we-need-to-privatize-ive-been-saying-it-for-years?itm_source=parsely-api">Marjorie Taylor Greene Pushes To Sell Off USPS Amid DOGE Momentum: &#8216;We Need To Privatize&#8230;I&#8217;ve Been Saying It For Years&#8217;</a>
The House removed a provision demanded by President-elect Donald Trump to suspend the federal debt limit, which had caused a Republican revolt on Thursday.
The Senate majority leader, Chuck Schumer (D-N.Y.), expressed confidence that the Senate would quickly pass the bill despite not including all Democratic priorities.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The House has overwhelmingly passed a bill to keep the government open and I'm confident the Senate will pass it as well. We hope to get it passed as soon as possible. Though this bill does not include everything Democrats fought for, there are major victories in this bill for…
&mdash; Chuck Schumer (@SenSchumer) <a href="https://twitter.com/SenSchumer/status/1870263553271226399?ref_src=twsrc%5Etfw">December 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The House&#8217;s decision followed a tumultuous week marked by Republican discord.
Speaker Mike Johnson (R-La.) had initially reached a bipartisan funding agreement with Democrats, but it was derailed by <a href="https://www.benzinga.com/general/social-media/24/12/42566558/house-republicans-reject-spending-bill-under-pressure-from-trump-musk-government-faces-shutdown">opposition from Trump</a> and Elon Musk.
To prevent a government shutdown set to begin at midnight on Friday, Republican leaders introduced a Plan C.
This approach involved holding separate votes on three key measures: a short-term funding bill to extend government operations for three months, a $100 billion disaster relief package, and a $10 billion bill for farm aid.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Sounds promising <a href="https://t.co/aNaCj0Jnfi">https://t.co/aNaCj0Jnfi</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1870139884385538550?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The bill&#8217;s passage is crucial to prevent a funding lapse at 12:01 a.m. Saturday, ensuring the continued operation of federal agencies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/12/42559347/trump-administration-could-ban-amazons-top-selling-routers-linked-to-chinese-cyberattacks-report?itm_source=parsely-api">Trump Administration Could Ban Amazon&#8217;s Top-Selling Routers Linked To Chinese Cyberattacks: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

House Passes Spending Bill To Avert Government Shutdown, Sidesteps Trump's Demand To Suspend Federal Debt Limit

ICCT

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) has outperformed the market over the past 20 years by 10.05% on an annualized basis producing an average annual return of 18.29%. Currently, Intuit has a market capitalization of $180.10 billion. 
Buying $1000 In INTU: If an investor had bought $1000 of INTU stock 20 years ago, it would be worth $29,211.80 today based on a price of $643.39 for INTU at the time of writing.
<h3>Intuit's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734738314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTU

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) has outperformed the market over the past 5 years by 38.28% on an annualized basis producing an average annual return of 51.25%. Currently, FTAI Aviation has a market capitalization of $13.69 billion. 
Buying $100 In FTAI: If an investor had bought $100 of FTAI stock 5 years ago, it would be worth $785.56 today based on a price of $133.49 for FTAI at the time of writing.
<h3>FTAI Aviation's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734737415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTAI

Here's How Much You Would Have Made Owning FTAI Aviation Stock In The Last 5 Years

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 10 years by 3.55% on an annualized basis producing an average annual return of 14.53%. Currently, Caterpillar has a market capitalization of $179.01 billion. 
Buying $100 In CAT: If an investor had bought $100 of CAT stock 10 years ago, it would be worth $390.57 today based on a price of $366.04 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734736508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Caterpillar 10 Years Ago Would Be Worth This Much Today

Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) has outperformed the market over the past 5 years by 6.51% on an annualized basis producing an average annual return of 19.48%. Currently, Morgan Stanley has a market capitalization of $198.32 billion. 
Buying $1000 In MS: If an investor had bought $1000 of MS stock 5 years ago, it would be worth $2,433.75 today based on a price of $123.10 for MS at the time of writing.
<h3>Morgan Stanley's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734735609_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

JIADE LIMITED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) (the "Company"), a company that specializes in providing one-stop comprehensive education supporting services to adult education institutions, today announced that the Company received a &nbsp;letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.&nbsp;

JDZG

JIADE Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) has outperformed the market over the past 15 years by 4.58% on an annualized basis producing an average annual return of 16.26%. Currently, Modine Manufacturing has a market capitalization of $6.24 billion. 
Buying $100 In MOD: If an investor had bought $100 of MOD stock 15 years ago, it would be worth $958.79 today based on a price of $118.89 for MOD at the time of writing.
<h3>Modine Manufacturing's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734734710_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Modine Manufacturing 15 Years Ago Would Be Worth This Much Today

On December 19, 2024, it was reported that Senator Markwayne Mullin executed a purchase of iShares MSCI Eurozone ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/EZU#BATS">EZU</a>) stock, valued between $100,001 and $250,000. The transaction, recorded in the December filing, was made on December 19, 2024.
At the time of writing, iShares MSCI Eurozone ETF shares are trading up 0.55% at $47.25.
<h3>Senator&#39;s Recent Trading Activity</h3>
In the past three years, Markwayne Mullin made 211 stock trades totaling more than $5.20 million. The largest trades involved stocks like Russell 1000 Ishares ETF and Invesco Actively Managed Exchange-Traded Fund Trus Invesco High Yield Select ETF. Their most notable trades made recently include key transactions:
<ul>
<li>Invesco Actively Managed Exchange-Traded Fund Trus Invesco High Yield Select ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/HIYS#BATS">HIYS</a>): $250,001 - $500,000 Purchase</li>
<li>iShares Core MSCI EAFE ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEFA#BATS">IEFA</a>): $100,001 - $250,000 Purchase</li>
<li>iShares MSCI Eurozone ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/EZU#BATS">EZU</a>): $100,001 - $250,000 Purchase</li>
</ul>
Here&#39;s a summary of Markwayne Mullin&#39;s recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>iShares Core MSCI EAFE ETF</td>
<td>IEFA</td>
<td>STOCK</td>
<td>$100,001 - $250,000</td>
<td>P</td>
<td>2024-11-27</td>
</tr>
<tr>
<td>iShares Core MSCI Emerging Markets ETF</td>
<td>IEMG</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-11-27</td>
</tr>
<tr>
<td>iShares MSCI Eurozone ETF</td>
<td>EZU</td>
<td>STOCK</td>
<td>$100,001 - $250,000</td>
<td>P</td>
<td>2024-11-27</td>
</tr>
<tr>
<td>Invesco Actively Managed Exchange Traded</td>
<td>&nbsp;</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>P</td>
<td>2024-11-12</td>
</tr>
<tr>
<td>Pimco Commoditiesplus Strategy Fund Class I-2</td>
<td>PCLPX</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S (Partial)</td>
<td>2024-11-12</td>
</tr>
</tbody>
</table>
<a href="https://www.benzinga.com/gov-trades?utm_source=insights-govtrades" rel="noopener noreferrer" target="_blank"><img alt="Gov Trades Image" src="https://www.benzinga.com/files/images/story/2024/1734714046_0.png" style="height:auto; max-width:100%" /></a>
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn&#39;t be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

General

HIYS

IEFA

This Senator Just Bought Up To $250K In iShares MSCI Eurozone ETF Stock

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 5 years by 21.25% on an annualized basis producing an average annual return of 34.22%. Currently, Murphy USA has a market capitalization of $10.53 billion. 
Buying $100 In MUSA: If an investor had bought $100 of MUSA stock 5 years ago, it would be worth $435.98 today based on a price of $519.99 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734733816_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MUSA

$100 Invested In Murphy USA 5 Years Ago Would Be Worth This Much Today

SkyBridge Capital founder Anthony Scaramucci has described Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) current price action as part of its typical cycle.
What Happened: In an <a href="https://x.com/Scaramucci/status/1870118849959399556">X</a> post on Friday, he explained that Bitcoin is purging leveraged, short-term momentum trades, a normal phenomenon in its market evolution.
However, Scaramucci also suggested that some altcoins may have experienced their "last hurrah" and could be done for good.
Meanwhile, crypto entrepreneur JC X <a href="https://x.com/Scaramucci/status/1870118849959399556">believes</a> human behaviour remains consistent: when Bitcoin surges, investors feel wealthier and take on more risks, often chasing gains in altcoins due to FOMO. This dynamic suggests altcoins may still have another rally in store.
In an interview, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42491094/anthony-scaramucci-upgrades-his-lamborghinibut-not-at-the-cost-of-selling-bitcoin-why-would-i-sell">Scaramucci expressed optimism</a> about Bitcoin&#8217;s future, stating he would never sell his holdings for luxury purchases. He emphasized Bitcoin's potential to attract <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42378636/scaramucci-bitcoin-is-a-volatile-asset-but-ready-for-prime-time-institutional-investing">mainstream institutional investment.</a>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42617815/are-microstrategys-bitcoin-purchases-on-hold-in-january">Are MicroStrategy&#8217;s Bitcoin Purchases On Hold In January?</a>
Why It Matters: Cathie Wood of ARK Invest remains bullish on Bitcoin, projecting a price of $1.5 million by 2030, citing its <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42609380/cathie-wood-says-bitcoin-is-more-scarce-than-gold-predicts-ma-surge-under-trump-2-0">scarcity compared to gold</a>. 
A 10x Research report highlighted macroeconomic challenges, including the Federal Reserve's hawkish stance, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42612972/bitcoins-2025-outlook-suddenly-looks-uncertain-heres-why">signaling a cautious year ahead</a> for traders and investors.
An expert from Foresight Ventures noted that Bitcoin's recent pullback marks its first significant correction since post-election euphoria. 
The analyst stated that <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42614273/bitcoin-crashes-10-ethereum-xrp-down-18-dogecoin-craters-28-what-is-going-on">20% corrections are typical</a> in bull markets, serving as consolidations rather than trend reversals.
Read Next: &nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42613106/have-risk-appetite-here-are-5-cryptos-that-could-make-your-christmas-merry">Have Risk Appetite? Here Are 5 Cryptos That Could Make Your Christmas Merry</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Anthony Scaramucci: Bitcoin's Moves Are 'Normal,' But Some Altcoins May Have Had Their 'Last Hurrah'

WIIM

Rumble shares are trading higher after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.

Adrian Alexandru, representing all similarly affected investors, has filed a federal securities class-action lawsuit against Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>), alleging the company violated <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40921732/applied-therapeutics-stock-soars-as-fda-scraps-panel-meeting-for-its-inherited-metabolic-disorder" rel="noreferrer noopener">federal securities laws</a>.
The lawsuit claims that the company provided misleading information about its clinical trials and failed to disclose key adverse facts, causing significant financial losses for shareholders.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40078613/rare-disease-focused-applied-therapeutics-lead-candidate-govorestat-has-blockbuster" rel="noreferrer noopener">Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside</a>
The class action covers investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024.
Central to the lawsuit are claims that the company touted positive results from its Phase 3 INSPIRE trial for govorestat for Galactosemia, without <a target="_blank" href="https://www.benzinga.com/24/11/42241059/regulatory-setback-for-applied-therapeutics-lead-program-fda-highlights-deficiencies-in-clinical-application" rel="noreferrer noopener">disclosing significant issues</a>. Bloomberg Law published a copy of the lawsuit online.
Allegations <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/AlexandruetalvAppliedTherapeuticsIncetalDocketNo124cv09715SDNYDec?doc_id=X6AM5BLRTI48QBRMPF9SKEGPKV0" rel="noreferrer noopener">include</a> problems with electronic data capture and dosing errors during the dose-escalation phase of the study, which were concealed from investors.
Investor confidence began to erode on November 27, 2024, when Applied Therapeutics received an FDA Complete Response Letter (CRL).
The CRL indicated that the agency could not approve the company's New Drug Application for govorestat in its current form, citing deficiencies in the clinical application.
Following the disclosure, Applied Therapeutics' stock price dropped sharply, which worsened after the company <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001697532/000095017024132306/aplt-20241202.htm" rel="noreferrer noopener">disclosed</a> receiving a warning letter from the FDA on December 2 highlighting unresolved clinical trial issues.
The FDA's warning letter pointed to electronic data capture problems and a dosing error that resulted in lower-than-targeted doses for some patients during the trial's early phase.
While Applied Therapeutics claims to have addressed these issues through detailed records and prior communications with the agency, investors reacted negatively to the revelations, further eroding the stock's value.
The lawsuit seeks to recover damages for investors who purchased shares at artificially inflated prices, alleging that the company's failure to provide accurate and complete information misled the market.
On Friday, Applied Therapeutics named John Johnson as executive chairman and announced that Shoshana Shendelman has stepped down as Chair and CEO. The company named Les Funtleyder, Applied Therapeutics' CFO, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42613049/applied-therapeutics-appoints-john-h-johnson-as-executive-chairman" rel="noreferrer noopener">as the interim CEO</a>.
RBC Capital analyst maintains Applied Therapeutics with a Sector Perform, lowering the price target from $4 to $1.5.
Price Action: APLT stock closed lower by 13.7% to $0.87 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42614476/whats-going-on-with-kroger-stock-after-revealing-5-billion-buyback" target="_blank" rel="noreferrer noopener">Kroger Launches $5 Billion Accelerated Share Repurchase: Details</a></li>
</ul>

Biotech

Health Care

APLT

Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 10 years by 27.08% on an annualized basis producing an average annual return of 38.07%. Currently, Comfort Systems USA has a market capitalization of $15.61 billion. 
Buying $100 In FIX: If an investor had bought $100 of FIX stock 10 years ago, it would be worth $2,552.04 today based on a price of $438.44 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734732908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Comfort Systems USA 10 Years Ago Would Be Worth Today

Stran &amp; Company, Inc. ("Stran" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAGW#NASDAQ">SWAGW</a>), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced that on December 17, 2024, it received a letter from the Listing Qualifications staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), issuing a Staff delisting determination (the "Staff Determination"). The Staff Determination noted that the Staff had notified the Company on June 21, 2024, August 23, 2024 and November 21, 2024 that the Company did not comply with Nasdaq Listing Rule 5250(c)(1) (the "Filing Rule") because the Company had not filed its Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, June 30, 2024, and September 30, 2024 (the "Forms 10-Q") with the Securities and Exchange Commission (the "SEC"). The Staff Determination noted that, based on the Staff's review and the materials submitted on August 20, 2024, the Staff granted the Company an exception until December 16, 2024 to regain compliance with the Filing Rule. The Staff Determination stated that the Company had not met the terms of the exception. Specifically, the Company has not filed the Forms 10-Q as required by the Filing Rule. The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company's common stock.

SWAG

SWAGW

Stran & Company Receives Nasdaq Staff Delisting Determination

Jiayin Group Inc. ("Jiayin" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>), a leading fintech platform in China, today announced that it entered into a definitive agreement on December 17, 2024 to purchase certain commercial property located in Shanghai, China (the "Commercial Property") of approximately 43,500 square meters for total cash consideration of approximately RMB1.35 billion. The completion of the purchase is subject to customary closing conditions. The Commercial Property will primarily be used as the Company's new headquarters to meet the demand arising from the continuing growth of the Company's businesses.

JFIN

Jiayin Group Announces Purchase Of Commercial Property Located In Shanghai, China For Total Cash Consideration Of ~RMB1.35 Billion

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Black Diamond Therapeutics (BDTX – Research Report),...

Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)

Gain Therapeutics (GANX) announced the presentation of a poster at the 36th EORTC-NCI-AACR, ENA, Symposium on molecular targets and cancer therapeu...

Gain Therapeutics presents data at 36th ENA symposium

"The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson'...

Gain Therapeutics reports Q3 EPS (17c), consensus (21c)

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS –&nbsp; Gain Therapeutics&nbsp;...

Closing Bell Movers: Applied Materials down 6% after earnings, guidance

Gain Therapeutics GAAP EPS of -$0.17

Keay Nakae, an analyst from Chardan Capital, reiterated the Buy rating on Gain Therapeutics (GANX – Research Report). The associated price target i...

Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson's Disease

Gain Therapeutics, Inc. ( ($GANX) ) has released its Q3 earnings. Here is a breakdown of the information Gain Therapeutics, Inc. presented to its i...

Gain Therapeutics Advances Parkinson's Therapy Development

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Gain Therapeutics (GANX – Research Report), with a price...

Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Trials

Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Gain Therapeutics (GANX) with a Buy rating and $7 price target Published first on TheF...

Gain Therapeutics initiated with a Buy at Roth MKM

Roth MKM analyst Boobalan Pachaiyappan last night initiated coverage of Gain Therapeutics (GANX) with a Buy rating and $7 price target The firm say...

Gain initiated with Buy on Parkison's potential at Roth MKM

AKYA

AMAT

ASND

ASTS

BDTX

CELC

DESP

DMRC

FLNT

GLOB

HOOK

INKT

IZEA

MSGM

OKLO

ORGN

POOL

SRFM

Press Releases

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics to Participate at Upcoming Investor Conferences

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

Comments

Gain Therapeutics

Noticias

Últimas noticias sobre Gain Therapeutics (NASDAQ:GANX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL